Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032695 · ClinicalTrials.gov registry record · Phase 3
Treatment of AIDS Vacuolar Myelopathy With Methionine
A Phase 3 study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Completed
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
NCT00032695: Completed Phase 3 study, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT00032695 is a Phase 3 study that has completed, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 56 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00032695, a Phase 3 study, has completed, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.
Interventions
- DRUG methionine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Phase | Phase 3 |
What the finished NCT00032695 record still lists
NCT00032695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which methionine is the first listed.
NCT00032695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00032695 about?
NCT00032695 is a clinical study titled "Treatment of AIDS Vacuolar Myelopathy With Methionine". The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.
What is the current status of trial NCT00032695?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 56 participants.
What interventions are being tested in trial NCT00032695?
The interventions under investigation include: methionine (DRUG).
Who is sponsoring clinical trial NCT00032695?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00032695's enrollment target sits among peer trials
56 1827th of 2000 higher than 167 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management